insights_auto
Why is DNA down 2.84%?
Dive Deeperchevron_right
DNA:NYSE
Ginkgo Bioworks Holdings Inc
$8.20
arrow_downward
-2.84%(-0.24) 1D
$8.10
arrow_downward
-1.22% (-0.100)todayPre-market
Closed: Nov 19, 4:00:04 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DNA...
Open
$8.61
High
$8.99
Low
$8.09
Mkt. cap
506.97M
Avg. vol.
2.59M
Volume
1.12K
52-wk high
$18.22
52-wk low
$5.37
EPS
-$4.19
Beta
1.74
Shares outstanding
53.94M
No. of employees
485
Open
$8.61
High
$8.99
Low
$8.09
Mkt. cap
506.97M
Avg. vol.
2.59M
Volume
1.12K
52-wk high
$18.22
52-wk low
$5.37
EPS
-$4.19
Beta
1.74
Shares outstanding
53.94M
No. of employees
485
News stories
From web sources and news partners
The Motley Fool
·
1 day ago
Is Anthropic’s IPO a Good Reason to Buy Ginkgo Bioworks Right Now?
Investing.com Canada
·
2 days ago
Form 144 Ginkgo Bioworks Holdings For: 17 November By Investing.com
Profile
Ginkgo Bioworks Holdings, Inc. is an American biotechnology company founded in 2008 by five scientists from MIT. The company uses genetic engineering to produce bacteria with industrial applications for other biotech companies, reducing the need for other companies to repeat the initial stages of synthetic biology design. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange through a SPAC merger on September 17, 2021. Wikipedia
About Ginkgo Bioworks Holdings Inc
CEOJason Kelly
Employees485
Founded2008
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
Industry-
Websiteginkgo.bio